These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17914417)

  • 1. A cost too high to bear? Prophylaxis versus preemptive therapy to prevent post-transplantation cytomegalovirus.
    Pescovitz MD
    Kidney Int; 2007 Oct; 72(8):912-3. PubMed ID: 17914417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation.
    Dmitrienko S; Yu A; Balshaw R; Shapiro RJ; Keown PA;
    Kidney Int; 2007 Oct; 72(8):1014-22. PubMed ID: 17700642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
    Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.
    Khoury JA; Storch GA; Bohl DL; Schuessler RM; Torrence SM; Lockwood M; Gaudreault-Keener M; Koch MJ; Miller BW; Hardinger KL; Schnitzler MA; Brennan DC
    Am J Transplant; 2006 Sep; 6(9):2134-43. PubMed ID: 16780548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
    Kacer M; Kielberger L; Bouda M; Reischig T
    Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Cost-Effective Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients Using Low-Dose Valganciclovir.
    Gheith O; Halim MA; Al-Otaibi T; Mansour H; Mosaad A; Atteya HA; Zakaria Z; Said T; Nair P; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):156-163. PubMed ID: 28260458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients.
    Kielberger L; Bouda M; Jindra P; Reischig T
    Kidney Blood Press Res; 2012; 35(6):407-16. PubMed ID: 22584353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
    Reischig T; Jindra P; Hes O; Svecová M; Klaboch J; Treska V
    Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: a single-center experience.
    Hellemans R; Beutels P; Ieven M; Verpooten GA; Bosmans JL
    Transpl Infect Dis; 2013 Feb; 15(1):70-8. PubMed ID: 23173691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation].
    Kawalec P; Holko P; Szkultecka-Debek M; Paszulewicz A; Boratyńska M; Głyda M; Ignacak E; Maks J; Russel-Szymczyk M; Kaweczyńska-Lasoń A
    Pol Merkur Lekarski; 2013 Jun; 34(204):332-8. PubMed ID: 23882930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation.
    Jung C; Engelmann E; Borner K; Offermann G
    Transplant Proc; 2001; 33(7-8):3621-3. PubMed ID: 11750538
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients.
    Luan FL; Kommareddi M; Ojo AO
    Transplantation; 2011 Jan; 91(2):237-44. PubMed ID: 21169881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
    Oppenheimer F; Gonzalez-Molina M; Rubio M
    Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Preemptive Therapy for Cytomegalovirus Disease in Pediatric Liver Transplantation.
    Nicastro E; Giovannozzi S; Stroppa P; Casotti V; Callegaro AP; Tebaldi A; Farina C; Colledan M; DʼAntiga L
    Transplantation; 2017 Apr; 101(4):804-810. PubMed ID: 27755504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
    Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF; Hodson EM; Jones C; Craig JC
    Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation.
    Matter-Walstra KW; Greiner M; Cusini A; Schiesser M; Ledergerber B; Fehr T; Mueller NJ
    Transpl Infect Dis; 2015 Jun; 17(3):342-9. PubMed ID: 25816700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.